Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
1. A method of reducing the incidence of mortality in a patient comprising administering to a patient in need thereof an effective amount of 5-amino-1-β-D-(5-benzylamino-5-deoxy-1-β-D-ribofuranosyl)imidazole-4-carboxamide, 5-amino-1-(5-amino-5-deoxy-β-D-ribofuranosyl) imidazole-4-N-[(4-chlorophenyl)methyl]carboxamide, or a salt thereof,
wherein, prior to initial administration, said patient has decreased left ventricular function as measured by an ejection fraction that is less than 30%, and
wherein, following the administration, the patient has improved left ventricular function.
2. A method of treating a patient with decreased left ventricular function having an ejection fraction that is less than 30% comprising administering to said patient in need thereof an effective amount of 5-amino-1-β-D-(5-benzylamino-5-deoxy-1-β-D-ribofuranosyl)imidazole-4-carboxamide, 5-amino-1-(5-amino-5-deoxy-β-D-ribofuranosyl) imidazole-4-N-[(4-chlorophenyl)methyl]carboxamide or a salt thereof,
wherein, prior to initial administration, said patient has decreased left ventricular function having an ejection fraction that is less than 30%, and
wherein, following the administration, the patient has improved left ventricular function.
3. The method of claim 1 or claim 2 wherein administration of 5-amino-1-β-D-(5-benzylamino-5-deoxy-1-β-D-ribofuranosyl)imidazole-4-carboxamide 5-amino-1-(5-amino-5-deoxy-β-D-ribofuranosyl) imidazole-4-N-[(4-chlorophenyl)methyl]carboxamide or a salt thereof provides a blood plasma concentration between about 1 μg/mL about 20 μg/mL.
4. The method of claim 1 or claim 2 wherein 5-amino-1-β-D-(5-benzylamino-5-deoxy-1-β-D-ribofuranosyl) imidazole-4-carboxamide is administered.
5. The method of claim 1 or claim 2 wherein 5-amino-1-(5-amino-5-deoxy-β-D-ribofuranosyl) imidazole-4-N-[(4-chlorophenyl)methyl]-carboxamide is administered.
6. The method of claim 1 or claim 2 wherein 5-amino-1-β-D-(5-benzylamino-5-deoxy-1-β-D-ribofuranosyl)imidazole-4-carboxamide, 5-amino-1-(5-amino-5-deoxy-β-D-ribofuranosyl) imidazole-4-N-[(4-chlorophenyl)methyl]carboxamide or a salt thereof is administered at 0.1 mg/kg/minute.
7. The method of claim 1 wherein said mortality is caused by a cardiovascular event.
8. The method of claim 7 , wherein said cardiovascular event is a myocardial infarction, dysrhythmia or ventricle dysfunction.
9. The method of claim 1 or 2 , wherein prior to administration, the patient has had a myocardial infarction.
10. The method of claim 1 or 2 , wherein the patient has had congestive heart failure.
11. The method of claim 9 , wherein the patient has had congestive heart failure.